The American Society of Clinical Oncology (ASCO) recently released a guideline focusing on ovarian cancer recurrence treatment. The guideline, Systemic Treatment of Ovarian Cancer Recurrence, aids clinicians in treating patients with epithelial, primary peritoneal, or fallopian tube carcinoma. The guideline features 17 recommendations resulting from six key research questions. For your convenience, we arranged the recommendations grouped with their associated research questions, below.
The 2026 ASCO Systemic Treatment of Ovarian Cancer Recurrence guideline is a living guideline that will be regularly updated following systematic reviews by a standing expert panel. For the most thorough look at the following recommendations, along with their qualifying statements, grading, rationale and more, view the full-text version.
Recommendations from the 2026 ASCO Guideline Systemic Treatment of Ovarian Cancer Recurrence
What is the recommended antineoplastic treatment of patients with recurrent platinum-sensitive epithelial ovarian cancer?
- Clinicians may offer a combination of PLD + carboplatin.
- Clinicians may offer paclitaxel + carboplatin.
- Clinicians may offer a combination of gemcitabine and carboplatin.
- Clinicians may offer bevacizumab in combination with a platinum-based doublet, followed by bevacizumab maintenance.
- Clinicians should not offer trabectedin in addition to PLD.
For patients with PSOC who have received and responded to treatment for recurrent ovarian cancer, what is the role of maintenance therapy?
- Clinicians may offer maintenance bevacizumab to patients PSOC who have responded to platinum-based therapy in combination with bevacizumab.
What is the role of surgery in patients with recurrent PSOC?
- There is insufficient evidence or Expert Panel agreement to provide a recommendation for or against secondary cytoreduction for patients with recurrent PSOC to guide clinical practice at this time.
- There is insufficient evidence or Expert Panel agreement to provide a recommendation for or against HIPEC for patients with recurrent PSOC to guide clinical practice at this time.
What is the recommended antineoplastic treatment of patients with recurrent PROC (systemic treatment)?
- Clinicians should offer mirvetuximab soravtansine for patients with high-grade PROC and validated results for positive FRα expression by IHC (75% of cells with ≥2+ [i.e., 2+ or 3+] staining intensity).
- Clinicians should offer PLD monotherapy.
- Clinicians should offer bevacizumab in combination with chemotherapy.
- Clinicians would offer paclitaxel with either a once weekly or once every three weeks schedule for administering paclitaxel.
- Clinicians may offer relacorilant and nab-paclitaxel.
- Clinicians may offer gemcitabine monotherapy as an option.
What is the role of surgery in the treatment of patients with recurrent PROC?
- For patients with PROC there is insufficient evidence to make a recommendation regarding the role of cytoreductive surgery in their treatment.
What is the recommended monitoring and/or surveillance strategy for patients after completion of therapy for recurrent ovarian cancer?
- Clinicians may offer clinical follow-up (monitoring) to patients with recurrent PSOC after completion of anti-cancer treatment.
- Clinicians may introduce ongoing specialty survivorship care for patients with PROC who have received first-line treatment.
Check out our latest oncology-related content and be sure to sign up for alerts to stay informed on the latest published guidelines and articles.